Moderna (MRNA) IV into BARDA additional $472M commitment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mail
Get Alerts MRNA Hot Sheet
Join SI Premium – FREE
Moderna (NASDAQ: MRNA) Moderna (NASDAQ: MRNA) July weekly call option implied volatility is at 97, August is at 102; compared to its 52-week range of 51 to 172 into Biomedical Advanced Research and Development Authority, or BARDA, making an additional commitment of up to $472M to support late stage clinical development including the expanded Phase 3 study of the company's mRNA vaccine candidate against COVID-19.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1 call to 1.6 puts as share price down 22%
- Eaton (ETN) spreaders of November 6 weekly 397.50, November 6 weekly 440, November 420 and November 470 calls as share price down 7%
- Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
